Cold Plasma Makes Tiny Magnesium Particles That Kill Cervical Cancer Cells

In a development that could reshape how scientists think about environmentally friendly nanomedicine, a research team at the University of Baghdad has shown that magnesium hydroxide nanoparticles, manufactured with nothing more exotic than a jet of cold helium plasma and a piece of high-purity magnesium wire, can destroy more than 80 percent of HeLa cervical cancer cells in laboratory cultures. The study, published in the Journal of Medical and Biological Engineering, describes a synthesis route that avoids the toxic chemical reducing agents traditionally required to build nanoparticles at this scale, and it reports a level of anticancer activity that has caught the attention of researchers working at the intersection of plasma physics and oncology.

The appeal of the technique lies in its simplicity. A cold plasma microjet is essentially a pencil-thin plume of ionized helium gas that remains close to room temperature even while it carries a menagerie of reactive species: electrons, ions, radicals, and energetic ultraviolet photons. When the researchers aimed this plume at magnesium wire submerged in liquid, the plasma’s chemistry attacked the metal surface, driving oxidation and dissolution reactions that ultimately precipitated magnesium hydroxide directly in the solution. Because no reducing chemicals are added at any stage, the process sidesteps many of the environmental and purification headaches associated with conventional wet-chemical nanoparticle synthesis, in which reagents such as sodium borohydride or organic solvents must later be removed from the final product.

To confirm that they had actually built what they intended to build, the team subjected their nanoparticles to a battery of characterization techniques. X-ray diffraction, which probes the arrangement of atoms by measuring how X-rays scatter from crystal planes, produced patterns that matched crystalline magnesium hydroxide exactly, and analysis of the peak widths revealed an average crystal size of approximately 10.5 nanometers. That is astonishingly small. For scale, a single human hair is roughly 7,000 times wider than one of these particles, and at that dimension the surface-to-volume ratio becomes enormous, meaning a large fraction of every particle’s atoms sit at the surface where they can interact directly with biological targets.

Scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy provided the second pillar of evidence. The electron micrographs showed particles with a near-spherical morphology and a tight, uniform distribution, while the accompanying elemental analysis confirmed high chemical purity with no detectable contaminant phases introduced by the plasma process. Perhaps most importantly for any eventual biomedical use, zeta potential measurements returned values between +30 and +40 millivolts. Zeta potential is a measure of the electrical charge a particle presents to its surroundings, and values of this magnitude indicate strong electrostatic repulsion between neighboring particles. In practical terms, the nanoparticles resist clumping together and settling out of suspension, which means a stable, well-dispersed formulation can be prepared and stored without specialized stabilizers.

With the material thoroughly characterized, the researchers turned to the question that drives most of nanomedicine: what does it do to cancer cells? They exposed HeLa cells, a famous and hardy line of cervical cancer cells first isolated in 1951, to nanoparticle concentrations ranging from 0.025 to 1.0 parts per million, then measured cell viability using the MTT assay at 24, 48, and 72 hours. The MTT assay relies on the fact that metabolically active cells reduce a yellow tetrazolium compound into purple formazan crystals; the amount of purple dye produced is directly proportional to the number of living, functioning cells. It is one of the most widely trusted readouts of cytotoxicity in cell biology, and the results here followed a clear and reproducible pattern.

Cell viability dropped steadily as both concentration and exposure time increased, a dose- and time-dependent relationship that is exactly what one expects from a genuine cytotoxic agent rather than a measurement artifact. At the highest concentration after 72 hours, cytotoxicity exceeded 80 percent, meaning that more than four out of every five cancer cells in the treated cultures had lost viability. Under the microscope, the researchers documented the physical consequences of that toxicity: treated cells visibly shrank and their membranes showed signs of damage, morphological hallmarks consistent with progressive cellular collapse rather than a transient growth slowdown.

The mechanism behind magnesium hydroxide’s anticancer effect is not fully mapped, and the study’s authors are careful on this point, emphasizing that the molecular pathways involved still need to be elucidated in future work. The existing literature, however, offers several plausible leads. Magnesium hydroxide is mildly alkaline and slowly releases hydroxide ions, which can perturb the delicate pH homeostasis that tumor cells work hard to maintain. Prior studies have shown that magnesium hydroxide nanoparticles can physically damage bacterial cell walls, raising the possibility that similar mechanical stress on the more fragile membranes of cancer cells contributes to the observed membrane damage. Related magnesium oxide nanoparticles have been linked to elevated reactive oxygen species, oxidative stress being one of the classic triggers of programmed cell death. Disentangling these candidate mechanisms, and determining which dominates at the low parts-per-million concentrations used in this study, is the obvious next experimental frontier.

The researchers are equally candid about the most important caveat: selectivity. A compound that kills cancer cells but harms healthy cells equally well is simply a poison, not a therapy. This study evaluated cytotoxicity exclusively against HeLa cells, so the question of how the nanoparticles behave toward normal cervical epithelial cells, fibroblasts, or other healthy tissue types remains open. Earlier work on magnesium-based nanomaterials has often reported favorable biocompatibility profiles, and magnesium itself is a biologically essential element that the human body regulates and tolerates well, which gives the field reason for optimism. But optimism is not evidence, and the authors explicitly call for comparative studies against normal cell lines before any clinical relevance can be claimed.

If those selectivity studies succeed, the potential applications extend beyond anticancer therapy. Magnesium hydroxide nanoparticles have already attracted interest as antibacterial agents, wound-dressing components, and drug-delivery platforms, with prior reports describing magnesium hydroxide nanocomposite hydrogels for infected wound care and fluorescent magnesium hydroxide nanosheets for antimicrobial bandages that also monitor wound pH. A synthesis method that is cheap, green, and reproducible, as the cold plasma microjet route demonstrably is, lowers the barrier to producing the quantities of well-defined nanomaterial that such applications demand. The plasma approach also produces the particles in a single step from a metallic precursor, avoiding the surfactants, high temperatures, and prolonged hydrothermal processing that other routes require.

What makes the study genuinely notable, then, is the combination of three results that rarely appear together: an unusually clean and sustainable synthesis, a rigorously characterized and colloidally stable product, and a striking biological effect at remarkably low concentrations. Parts per million is an extraordinary range in which to see strong cytotoxicity, and if future work confirms that the effect is selective for transformed cells, cold-plasma-synthesized magnesium hydroxide nanoparticles could move from the physics lab toward preclinical evaluation. For now, the study stands as a persuasive demonstration that one of the most extreme tools in modern physics can craft one of chemistry’s humblest compounds into a serious candidate for cancer research, and it offers a template for how plasma science and biomedicine can be married to greener effect.

The choice of helium as the plasma-forming gas is itself worth noting. Helium’s high ionization energy and low breakdown voltage make it the workhorse gas for atmospheric-pressure plasma jets, producing a discharge that is dense in reactive oxygen and nitrogen species yet gentle enough to operate in open air near liquid surfaces. Researchers in the same laboratory group have previously applied this technique to other materials, including zinc oxide, copper oxide, iron oxide, and selenium nanoparticles, suggesting that the microjet platform functions as a general-purpose synthesis tool rather than a one-off method tailored to a single compound.

The positive surface charge reported for the particles also has biological implications beyond shelf stability. Positively charged nanoparticles generally interact more readily with the negatively charged membranes of mammalian cells, which can promote cellular uptake through endocytosis. Prior work on related magnesium-based nanomaterials has traced toxicity to caveolin-1-mediated endocytosis in endothelial cells, illustrating how surface charge and internalization pathways can shape a nanoparticle’s biological behavior.

The concentration range examined here deserves emphasis. At 0.025 to 1.0 parts per million, the effective doses are far below those typically reported for many metal oxide nanoparticles in similar assays, where tens or hundreds of parts per million are often required to achieve comparable killing. Whether this heightened potency reflects the small crystal size, the high purity, the colloidal stability, or some combination of these properties remains an open question that comparative studies against conventionally synthesized magnesium hydroxide could resolve.

It is also useful to place the safety picture in context. Animal studies of magnesium oxide nanoparticles have generally found limited acute toxicity, and investigations of magnesium hydroxide nanoparticles in normal biological systems have reported favorable biosafety profiles at antibacterial doses. That record, combined with magnesium’s status as an essential physiological element, provides a plausible foundation for the selectivity studies the authors now call for, though in vitro potency at parts-per-million levels will need careful re-examination in more complex biological systems before therapeutic claims can be entertained.

Subject of Research: Cold plasma synthesis of magnesium hydroxide nanoparticles and their in vitro cytotoxicity against HeLa cervical cancer cells.

Article Title: Cold Plasma Synthesis Mg(OH)₂ Nanoparticles: In Vitro Cytotoxic Evaluation Against HeLa Cervical Cancer Cells

Article References: saad akram, R., Majeed, N. F., Abdalameer, N. K., & Zaydan, E. A. (2026). Cold Plasma Synthesis Mg(OH)₂ Nanoparticles: In Vitro Cytotoxic Evaluation Against HeLa Cervical Cancer Cells. Journal of Medical and Biological Engineering. https://doi.org/10.1007/s40846-026-01055-5

Image Credits: AI Generated

DOI: 10.1007/s40846-026-01055-5

Keywords: cold plasma, magnesium hydroxide, nanoparticles, HeLa cells, cervical cancer, cytotoxicity, MTT assay, green synthesis, nanomedicine, biomedical engineering, X-ray diffraction, zeta potential